Innoviva, Inc. Common Stock INVA
$21.34
+2.89%
at last close
Market Cap$1.50 billion
P/E Ratio5.19
Div Yield4.69%
Volume515.3K
52-Week Range
$16.52$25.14
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 0 Hold · 1 Sell (5 analysts)
- Avg. Price Target
- $34.80 (+63.1% upside)
Key Stats
- Today's Range
- $20.59 – $21.39
- 50-Day Range
- $20.20 – $22.09
- 52-Week Range
- $16.52 – $25.14
- Volume
- 515K shs
- Average Volume
- 863K shs
- Market Cap
- $1.50 billion
- P/E Ratio
- 5.19
- Dividend Yield
- 4.69%
Valuation
- P/E Ratio
- 5.19
- Price / Book
- 1.21
- Price / Sales
- 3.41
Dividend
- Dividend Yield
- 4.69%
- Annual Dividend
- $1.00
- Payout Ratio
- 24.33%
- Ex-Dividend Date
- 2015-09-08
Short Interest
- Short Interest
- 19.43%
- Days to Cover
- 20.53
Financials (TTM)
- Revenue
- $440.00 million
- Net Income
- $357.24 million
- Net Margin
- 81.19%
- Return on Equity
- 28.97%
- Debt-to-Equity
- —
About Innoviva, Inc. Common Stock
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Related Stocks
Compare head-to-head: INVA vs LLY·INVA vs JNJ·INVA vs ABBV·INVA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.